share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  06/06 08:56

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.
Allarity Therapeutics, Inc. has reported a significant change in its executive management structure through a filing with the SEC. The company, based in Delaware and listed under the ticker ALLR on the Nasdaq Stock Market, disclosed the replacement of a consultancy agreement with a new Management Services Agreement (MSA) with Ljungaskog Consulting AB, effective June 1, 2024. This new agreement engages Thomas H. Jensen, the CEO of Allarity Therapeutics, to continue his services with a fixed monthly fee of $43,750 and a one-time signing bonus of $100,000. The MSA outlines performance-based compensation adjustments, eligibility for annual discretionary performance bonuses, and expense reimbursements. It also details termination provisions for both the company and the consultant, including termination for convenience and for cause, with specific financial implications. The MSA supersedes the previous consultancy agreement and is set to continue until the agreed termination conditions are met. The full text of the MSA is included as Exhibit 10.1 in the SEC filing.
Allarity Therapeutics公司向美国证券交易委员会提交文件,披露了其高管管理架构的重大变化。这家总部位于特拉华州,以股票代号ALLR在纳斯达克证券交易所上市的公司,披露了与Ljungaskog Consulting AB签订全新的管理服务协议(MSA),自2024年6月1日起生效。新协议约定了Allarity Therapeutics首席执行官Thomas H. Jensen以固定月收入$43,750和一次性签约奖金$100,000的方式继续提供服务,并详细规定了基于业绩的薪酬调整、参与年度福利奖金、费用报销等细节。此外,协议也为公司和顾问的终止条款规定了相应的财务影响,包括方便和原因的终止。该协议取代前一份咨询协议,将继续有效直到达成约定的终止条件。MSA的全部内容作为附件10.1附在提交给美国证券交易委员会的文件中。
Allarity Therapeutics公司向美国证券交易委员会提交文件,披露了其高管管理架构的重大变化。这家总部位于特拉华州,以股票代号ALLR在纳斯达克证券交易所上市的公司,披露了与Ljungaskog Consulting AB签订全新的管理服务协议(MSA),自2024年6月1日起生效。新协议约定了Allarity Therapeutics首席执行官Thomas H. Jensen以固定月收入$43,750和一次性签约奖金$100,000的方式继续提供服务,并详细规定了基于业绩的薪酬调整、参与年度福利奖金、费用报销等细节。此外,协议也为公司和顾问的终止条款规定了相应的财务影响,包括方便和原因的终止。该协议取代前一份咨询协议,将继续有效直到达成约定的终止条件。MSA的全部内容作为附件10.1附在提交给美国证券交易委员会的文件中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息